BME
Every company in the roster listed on BME.
Every company in the roster listed on BME.
5 of 5 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
AlmirallALM · BME | 5 assets: 3 approved, 1 Ph 3, 1 other | Almotriptan (Axert)US approval withdrawn · MigraineWeak signal | 25 Apr 2027lebrikizumab · Phase 3 | — | $405MJun 2026 | — | — |
GrifolsGRF · BME | 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)Phase 3 | None on record | — | $970MDec 2025 | — | $483M |
Laboratorios Farmacéuticos Rovi, S.A.ROVI · BME | 1 asset: 1 Ph 1 | Risperidone (QUAR)Phase 1 · SchizophreniaWeak signal | None on record | — | — | — | — |
Oryzon Genomics, S.A.ORY · BME | 1 asset: 1 Ph 2 | IadademstatPhase 2 · Acute Myeloid LeukemiaWeak signal | None on record | — | $33MDec 2025 | ~8.3 qtrs | $14M |
PharmaMarPHM · BME | 2 assets: 1 approved, 1 Ph 3 | PlitidepsinPhase 3 · Multiple MyelomaPartial signal | 31 Dec 2027Lurbinectedin · Phase 3 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.